Fenofibrate causes regression of endometriotic implants: a rat model
Lab / animal
OA: closed
CC0
⤵ 11 in-corpus citations
AI-generated summary
This study investigated the effects of fenofibrate on endometriotic implants in a rat model, finding that fenofibrate treatment led to the regression of these implants.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Fenofibrate -a peroxisome proliferator-activated receptor-a agonist- is an angiostatic agent that is commonly used in human liver diseases, therefore it may interfere with the angiogenetic process required for endometriosis. In a rat endometriosis model, we demonstrated that peritoneal implant areas and vascular endothelial growth factor levels in the peritoneal flud were significantly decreased in high dose or low dose finofibrate and luprolide acetate treated groups compared to control.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (18)
- Angiogenic factors in endometriosis via openalex
- Antiangiogenic therapies in endometriosis via openalex
- Genistein causes regression of endometriotic implants in the rat model via openalex
- High-dose atorvastatin causes regression of endometriotic implants: a rat model via openalex
- Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity via openalex
- Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib via openalex
- Serial analysis of gene expression reveals differential expression between endometriosis and normal endometrium. Possible roles for AXL and SHC1 in the pathogenesis of endometriosis via openalex
- W2039120010 via openalex
- W2088386132 via openalex
- W2012410138 via openalex
- W2104224178 via openalex
- W2113328569 via openalex
- W1996126594 via openalex
- W2126728673 via openalex
- W1978736810 via openalex
- W2278759672 via openalex
- W2034278235 via openalex
- W2397291750 via openalex
Cited by (11)
- Endometriosis-Associated Angiogenesis and Anti-angiogenic Therapy for Endometriosis 2022
- The Effect of Novel Medical Nonhormonal Treatments on the Angiogenesis of Endometriotic Lesions 2021
- Lipidomic Alterations and PPARα Activation Induced by Resveratrol Lead to Reduction in Lesion Size in Endometriosis Models 2021
- Anti-Angiogenic Alternative and Complementary Medicines for the Treatment of Endometriosis: A Review of Potential Molecular Mechanisms 2018
- New developments in the medical treatment of endometriosis 2017
- An Update on Pathophysiology and Medical Management of Endometriosis 2016
- Novel Medical Treatment Modalities of Endometriosis 2015
- Sunitinib as an anti-endometriotic agent 2013
- Anti-angiogenic treatment strategies for the therapy of endometriosis 2012
- The translational challenge in the development of new and effective therapies for endometriosis: a review of confidence from published preclinical efficacy studies 2011
- Evolving spectrum: the pathogenesis of endometriosis 2010
Source provenance
- europepmc
- last seen: 2026-10-16T06:09:50.462052+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:06:42.330992+00:00
- unpaywall
- last seen: 2026-09-17T06:32:46.214484+00:00
License: CC0
· commercial use OK